Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Francesca Palandri; Giuseppe A Palumbo; Massimiliano Bonifacio; Massimo Breccia; Roberto Latagliata; Bruno Martino; Nicola Polverelli; Elisabetta Abruzzese; Mario Tiribelli; Maura Nicolosi; Micaela Bergamaschi; Alessia Tieghi; Alessandra Iurlo; Nicola Sgherza; Francesco Cavazzini; Alessandro Isidori; Gianni Binotto; Adalberto Ibatici; Monica Crugnola; Florian Heidel; Costanza Bosi; Daniela Bartoletti; Giuseppe Auteri; Lucia Catani; Antonio Cuneo; Franco Aversa; Gianpietro Semenzato; Michele Cavo; Nicola Vianelli; Giulia Benevolo

doi:10.1016/j.leukres.2018.10.001

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Leuk Res. 2018 Nov:74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5.

Authors

Francesca Palandri¹, Giuseppe A Palumbo², Massimiliano Bonifacio³, Massimo Breccia⁴, Roberto Latagliata⁴, Bruno Martino⁵, Nicola Polverelli⁶, Elisabetta Abruzzese⁷, Mario Tiribelli⁸, Maura Nicolosi⁹, Micaela Bergamaschi¹⁰, Alessia Tieghi¹¹, Alessandra Iurlo¹², Nicola Sgherza¹³, Francesco Cavazzini¹⁴, Alessandro Isidori¹⁵, Gianni Binotto¹⁶, Adalberto Ibatici¹⁷, Monica Crugnola¹⁸, Florian Heidel¹⁹, Costanza Bosi²⁰, Daniela Bartoletti²¹, Giuseppe Auteri²¹, Lucia Catani²¹, Antonio Cuneo¹⁴, Franco Aversa¹⁸, Gianpietro Semenzato¹⁶, Michele Cavo²¹, Nicola Vianelli²¹, Giulia Benevolo⁹

Affiliations

¹ Institute of Hematology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy. Electronic address: francesca.palandri@unibo.it.
² Division of Hematology, AOU "Policlinico-V. Emanuele", University of Catania, Catania, Italy.
³ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
⁴ Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy.
⁵ Division of Hematology, Azienda Ospedaliera 'Bianchi Melacrino Morelli', Reggio Calabria, Italy.
⁶ Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
⁷ Division of Hematology, Ospedale S. Eugenio, Roma, Italy.
⁸ Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
⁹ Division of Hematology, Città della Salute e della Scienza Hospital, Torino, Italy.
¹⁰ Clinic of Hematology, Department of Internal Medicine (DiMI), IRCCS AOU San Martino-IST, Genova, Italy.
¹¹ Division of Hematology, Azienda Ospedaliera-IRCSS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
¹² Hematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy.
¹³ Division of Hematology, Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
¹⁴ Division of Hematology, University of Ferrara, Ferrara, Italy.
¹⁵ Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
¹⁶ Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy.
¹⁷ Division of Hematology and Bone Marrow Transplant, IRCCS San Martino-IST, Genova, Italy.
¹⁸ Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
¹⁹ Internal Medicine II, Hematology and Oncology, Friedrich-Schiller-University Medical Center, Jena, Germany.
²⁰ Division of Hematology, AUSL di Piacenza, Piacenza, Italy.
²¹ Institute of Hematology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

PMID: 30321784
DOI: 10.1016/j.leukres.2018.10.001

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Multicenter Study

MeSH terms

Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Organ Size / drug effects
Primary Myelofibrosis* / drug therapy
Primary Myelofibrosis* / metabolism
Primary Myelofibrosis* / pathology
Rituximab / administration & dosage*
Spleen* / metabolism
Spleen* / pathology
Time Factors

Substances

Rituximab